230 related articles for article (PubMed ID: 33539729)
1. 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.
Hoskin P; Popova B; Schofield O; Brammer C; Robinson M; Brunt AM; Madhavan K; Illidge T; Gallop-Evans E; Syndikus I; Clifton-Hadley L; Kirkwood AA
Lancet Oncol; 2021 Mar; 22(3):332-340. PubMed ID: 33539729
[TBL] [Abstract][Full Text] [Related]
2. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial.
Hoskin PJ; Kirkwood AA; Popova B; Smith P; Robinson M; Gallop-Evans E; Coltart S; Illidge T; Madhavan K; Brammer C; Diez P; Jack A; Syndikus I
Lancet Oncol; 2014 Apr; 15(4):457-63. PubMed ID: 24572077
[TBL] [Abstract][Full Text] [Related]
3. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Dearnaley D; Syndikus I; Mossop H; Khoo V; Birtle A; Bloomfield D; Graham J; Kirkbride P; Logue J; Malik Z; Money-Kyrle J; O'Sullivan JM; Panades M; Parker C; Patterson H; Scrase C; Staffurth J; Stockdale A; Tremlett J; Bidmead M; Mayles H; Naismith O; South C; Gao A; Cruickshank C; Hassan S; Pugh J; Griffin C; Hall E;
Lancet Oncol; 2016 Aug; 17(8):1047-1060. PubMed ID: 27339115
[TBL] [Abstract][Full Text] [Related]
4. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
5. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
Coles CE; Griffin CL; Kirby AM; Titley J; Agrawal RK; Alhasso A; Bhattacharya IS; Brunt AM; Ciurlionis L; Chan C; Donovan EM; Emson MA; Harnett AN; Haviland JS; Hopwood P; Jefford ML; Kaggwa R; Sawyer EJ; Syndikus I; Tsang YM; Wheatley DA; Wilcox M; Yarnold JR; Bliss JM;
Lancet; 2017 Sep; 390(10099):1048-1060. PubMed ID: 28779963
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A; Haviland JS; Wheatley DA; Sydenham MA; Alhasso A; Bloomfield DJ; Chan C; Churn M; Cleator S; Coles CE; Goodman A; Harnett A; Hopwood P; Kirby AM; Kirwan CC; Morris C; Nabi Z; Sawyer E; Somaiah N; Stones L; Syndikus I; Bliss JM; Yarnold JR;
Lancet; 2020 May; 395(10237):1613-1626. PubMed ID: 32580883
[TBL] [Abstract][Full Text] [Related]
7. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
8. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J; Holm T; Pettersson D; Berglund Å; Cedermark B; Radu C; Johansson H; Machado M; Hjern F; Hallböök O; Syk I; Glimelius B; Martling A
Lancet Oncol; 2017 Mar; 18(3):336-346. PubMed ID: 28190762
[TBL] [Abstract][Full Text] [Related]
9. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.
Chow E; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JS; Brundage MD; Nabid A; Tissing-Tan CJ; Oei B; Babington S; Demas WF; Wilson CF; Meyer RM; Chen BE; Wong RK
Lancet Oncol; 2014 Feb; 15(2):164-71. PubMed ID: 24369114
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
11. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
Coles CE; Haviland JS; Kirby AM; Griffin CL; Sydenham MA; Titley JC; Bhattacharya I; Brunt AM; Chan HYC; Donovan EM; Eaton DJ; Emson M; Hopwood P; Jefford ML; Lightowlers SV; Sawyer EJ; Syndikus I; Tsang YM; Twyman NI; Yarnold JR; Bliss JM;
Lancet; 2023 Jun; 401(10394):2124-2137. PubMed ID: 37302395
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
[TBL] [Abstract][Full Text] [Related]
14. Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C; Finneran L; Roe J; Sydenham MA; Beasley M; Bhide S; Boon C; Cook A; De Winton E; Emson M; Foran B; Frogley R; Petkar I; Pettit L; Rooney K; Roques T; Srinivasan D; Tyler J; Hall E;
Lancet Oncol; 2023 Aug; 24(8):868-880. PubMed ID: 37423227
[TBL] [Abstract][Full Text] [Related]
15. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
18. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
19. Palliative radiotherapy after oesophageal cancer stenting (ROCS): a multicentre, open-label, phase 3 randomised controlled trial.
Adamson D; Byrne A; Porter C; Blazeby J; Griffiths G; Nelson A; Sewell B; Jones M; Svobodova M; Fitzsimmons D; Nixon L; Fitzgibbon J; Thomas S; Millin A; Crosby T; Staffurth J; Hurt C
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):292-303. PubMed ID: 33610215
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
